In 21 patients ( age 74 + / -9 years ) with extensive coronary artery disease not eligible for coronary artery bypass surgery , the effect of granulocyte-macrophage colony-stimulating factor ( GM-CSF , Molgramostim ) on quantitatively assessed collateral flow was tested in a randomized , double-blind , placebo-controlled fashion .
